On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $322.83, a high estimate of $400.00, and a low estimate of $220.00.

During the last three months, 24 analysts shared their evaluations of Alnylam Pharmaceuticals ALNY, revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dozens more are in clinical testing. Yet the field's best-known companies, led by Alnylam Pharmaceuticals, have only taken RNAi so far. Their drugs are still largely focused on disease targets in the ...

AbbVie and Alnylam Pharmaceuticals witnessed comparable market capitalisation growth, with AbbVie reporting 15.2% and Alnylam Pharmaceuticals 14.9% over Q3 2024. AbbVie’s growth was driven by the ...

In the last three months, 24 analysts have published ratings on Alnylam Pharmaceuticals ALNY, offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...

In recent weeks, global markets have been buoyed by a strong rally in U.S. stocks, driven by optimism surrounding potential policy shifts following the Republican "red sweep" in the elections. The ...

Alnylam Pharmaceuticals Inc (NASDAQ ... driven by a gross to net adjustment in Portugal and large orders in partner markets in Q2. Net revenue from collaborations decreased by $370 million ...